title: [Ocular hypertension after intravitreal steroid injections: Clinical update as of 2015].
abstract: Intravitreal injections are a therapeutic delivery method best suited to the treatment of retinal diseases. Recent years have been marked by the use of anti-VEGF agents as well as the arrival of sustained-release corticosteroid implants in France, replacing triamcinolone acetonide. A common complication of IVT steroids is secondary ocular hypertension (OHT) resulting from increased outflow resistance. This article summarizes current understanding. OHT induced by topical steroids has been described for 60 years. Intravitreal use also shows a temporary effect if the exposure is short, dose dependence, and varying incidence depending on the drug used. Sustained release formulations and discontinuing treatment have reduced the risk of induced OHT. Risk factors that induce OHT must be clearly identified prior to an injection. Most cases of OHT can be controlled medically, although differences exist between different drugs. In cases where it cannot be controlled, removal of the implant, selective laser trabeculoplasty, and filtration surgery can be discussed.
authors.affiliation: HIA Desgenettes, 108, boulevard Pinel, 69275 Lyon cedex 03, France. Electronic address: corinnedot.pro@hotmail.fr.
authors.forename: C
authors.initials: C
authors.lastname: Dot
authors.affiliation: HIA Desgenettes, 108, boulevard Pinel, 69275 Lyon cedex 03, France.
authors.forename: H
authors.initials: H
authors.lastname: El Chehab
authors.affiliation: HIA Desgenettes, 108, boulevard Pinel, 69275 Lyon cedex 03, France.
authors.forename: A
authors.initials: A
authors.lastname: Russo
authors.affiliation: HIA Desgenettes, 108, boulevard Pinel, 69275 Lyon cedex 03, France.
authors.forename: E
authors.initials: E
authors.lastname: Agard
mesh_terms: D000086:Acetazolamide / Q000627:therapeutic use; D000305:Adrenal Cortex Hormones / Q000008:administration & dosage / Q000009:adverse effects*; D000328:Adult; D000818:Animals; D002648:Child; D003692:Delayed-Action Preparations; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D004343:Drug Implants; D018463:Filtering Surgery; D005446:Fluocinolone Acetonide / Q000008:administration & dosage / Q000009:adverse effects; D006801:Humans; D058449:Intravitreal Injections; D009798:Ocular Hypertension / Q000139:chemically induced* / Q000188:drug therapy / Q000517:prevention & control / Q000601:surgery; D009824:Ointments; D009883:Ophthalmic Solutions; D011817:Rabbits; D012164:Retinal Diseases / Q000188:drug therapy; D012307:Risk Factors; D014222:Triamcinolone Acetonide / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D000305:Adrenal Cortex Hormones; D003692:Delayed-Action Preparations; D004343:Drug Implants; D009824:Ointments; D009883:Ophthalmic Solutions; D005446:Fluocinolone Acetonide; D003907:Dexamethasone; D014222:Triamcinolone Acetonide; D000086:Acetazolamide
keywords: Corticoïdes; Hypertonie oculaire; Injection intra-vitréenne; Intravitreal injection; Ocular hypertension; Steroids